10X Genomics Inc (TXG)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $7.23B
Last updated: Nov 17, 2026 at 4:43 PM ET
10X Genomics Inc (TXG) Statistics
10X Genomics (TXG) has a market cap of $7.23B and an enterprise value of $6.71B. Its share count is up 4.23% from a year earlier. It kept -10.84% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 7.27% below the market cap, as cash exceeds debt.
| Market Cap | $7.23B |
|---|---|
| Enterprise Value | $6.71B |
| Latest price (Nov 17, 2026) | $56.30 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 11.9x and 8.8x. Its year-end P/S ranged from 2.8x to 48.3x from 2019 to 2025.
| P/S Ratio | 11.9x |
|---|---|
| Forward P/S | 11.5x |
| P/B Ratio | 8.8x |
| P/TBV Ratio | 9.5x |
| P/FCF Ratio | 78.5x |
| P/OCF Ratio | 72.5x |
Enterprise Valuation
Counting debt and cash, the company is valued at 72.9x free cash flow.
| EV / Sales | 10.8x |
|---|---|
| EV / FCF | 72.9x |
Price Statistics
The stock is up 254.31% over 52 weeks and trades 23.48% below its 50-day average.
| Beta (1Y) | 2.48 |
|---|---|
| 52-Week Change | +254.31% |
| 1-Month Change | -19.44% |
| 3-Month Change | -9.47% |
| 6-Month Change | +152.58% |
| 5-Year Change | -56.53% |
| Total Return (1Y) | +254.31% |
| Total Return (3Y CAGR) | +10.11% |
| Total Return (5Y CAGR) | -17.78% |
| Return vs SPY (1Y) | +250.27% |
| Max Drawdown (1Y) | -43.74% |
| Max Drawdown (3Y) | -87.59% |
| Sharpe Ratio (1Y) | 1.70 |
| Correlation with SPY (1Y) | 0.45 |
| 50-Day Average | $73.58 |
| 200-Day Average | $42.93 |
| 52-Week Range | $15.18 to $102.81 |
| RSI (14 Days) | 38.5 |
| Average Volume (20 Days) | 3.22M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.12x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 5.12x |
|---|---|
| Quick Ratio | 4.66x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -8.00% over the last 12 months, against a 5-year average of -18.67%.
| Return on Equity (ROE) | -8.00% |
|---|---|
| Return on Assets (ROA) | -6.31% |
| ROE (5Y Average) | -18.67% |
| ROA (5Y Average) | -14.47% |
| ROIC (5Y Average) | -7.53% |
| Asset Turnover | 0.59x |
| Inventory Turnover | 2.97x |
| Receivables Turnover | 11.31x |
| Cash Conversion Cycle | 111 days |
Scores
TXG has an Altman Z-Score of 18.54, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 18.54 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $618.58M over the last 12 months is down 3.62% from the 12 months before.
| Revenue | $618.58M |
|---|---|
| Revenue Growth (YoY) | -3.62% |
| Gross Profit | $444.65M |
| Operating Income | -$72.20M |
| Pretax Income | -$65.16M |
| Net Income | -$67.08M |
| EBITDA | -$43.70M |
| Reported EPS (TTM) | -$0.15 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 79.06% of the $1.06B in total assets.
| Cash and Equivalents | $526.19M |
|---|---|
| Total Debt | $0 |
| Net Cash | $526.19M |
| Net Cash Per Share | $4.02 |
| Working Capital | $578.26M |
| Shareholder Equity | $838.04M |
| Book Value Per Share | $6.41 |
| Tangible Book Value | $772.46M |
| Tangible Book Per Share | $5.91 |
| Total Assets | $1.06B |
| Total Liabilities | $225.09M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $5.93M of capital spending, operating cash flow left $93.77M of free cash flow.
| Operating Cash Flow | $99.70M |
|---|---|
| Capital Expenditures | $5.93M |
| Free Cash Flow | $93.77M |
| FCF Per Share | $0.78 |
| Depreciation and Amortization | $43.18M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -11.67%, against a 5-year average of -25.48%.
| Gross Margin | 71.88% |
|---|---|
| Operating Margin | -11.67% |
| Pretax Margin | -10.53% |
| Net Margin | -10.84% |
| EBITDA Margin | -7.07% |
| FCF Margin | 15.16% |
| Gross Margin (5Y Average) | 72.93% |
| Operating Margin (5Y Average) | -25.48% |
| Net Margin (5Y Average) | -24.38% |
Growth
Revenue grew 7.57% a year over 3 years.
| Revenue Growth (3Y CAGR) | +7.57% |
|---|---|
| Revenue Growth (5Y CAGR) | +16.55% |
| Book Value Per Share Growth (2Y CAGR) | +0.13% |
| Tangible Book Per Share Growth (2Y CAGR) | -2.77% |
Dividends and Yields
TXG does not pay a dividend. Its free cash flow yield is 1.27%.
| FCF Yield | 1.27% |
|---|---|
| Buyback Yield | -0.19% |
| Shareholder Yield | -0.19% |
Peer Position
Against 11 similar companies, TXG has the highest P/S.
P/S RatioPeer median 3.2x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +7.91%
| P/S Ratio | 11.9x vs 3.2x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -3.62% vs +7.91% median |
Analyst Forecast
Consensus estimates put revenue growth at 4.72% and EPS growth at -38.60% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +4.72% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -38.60% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TXG
What is TXG's market cap?
10X Genomics has a market cap of $7.23B. Its enterprise value, which adds debt and subtracts cash, is $6.71B.
How many shares of TXG are outstanding?
10X Genomics has 130.81M shares outstanding. The count is up 4.23% from a year earlier.
Does TXG pay a dividend?
No. 10X Genomics does not pay a dividend.
How much debt does TXG have?
10X Genomics has $0 of total debt and $526.19M of cash and equivalents, a net cash position of $526.19M.
TXG pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts